Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2026 18:00 ET | Source: Biogen Inc.

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpointsBased on data from the Phase 2b LUMA study, Biogen and Denali will discontinue...
May 21, 2026 18:00 ET | Source: Denali Therapeutics Inc.

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue...
May 21, 2026 17:39 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse eventsActivity of the combined regimen...
May 21, 2026 17:30 ET | Source: Crescent Biopharma, Inc.

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients ...
May 21, 2026 17:30 ET | Source: Peace Acquisition Corp.

Peace Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering

NEW YORK, NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Peace Acquisition Corp (the “Company”) announced today that it priced its initial public offering of 6,000,000 units at $10.00 per unit. The...
May 21, 2026 17:29 ET | Source: Pliant Therapeutics, Inc.

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant...
May 21, 2026 17:25 ET | Source: VCI Global Limited

VCI Global Received NASDAQ Notice Related to Late Filing of 20-F

KUALA LUMPUR, Malaysia, May 21, 2026 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”) today announced that it received a notification letter from the Nasdaq...
May 21, 2026 17:21 ET | Source: Aktis Oncology Inc.

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors

Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingCombined results evaluating AKY-2519 across several B7-H3 expressing tumor types,...
May 21, 2026 17:15 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Cash Runway Extended to Finance the Parkinson’s Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS)...
May 21, 2026 17:13 ET | Source: Black Diamond Therapeutics, Inc

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

Preliminary mPFS of 15.2 months; mDOR not reachedRobust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastasesORR 60% in patients with a broad spectrum of EGFR-NCMs, including...